Skites Pharma Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 5.94 Cr
as on 16-11-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 79.92 Cr
as on 16-11-2024
- Revenue 39.55%
(FY 2023)
- Profit 0.50%
(FY 2023)
- Ebitda 427.49%
(FY 2023)
- Net Worth -13.56%
(FY 2023)
- Total Assets 38.53%
(FY 2023)
About Skites Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 5.94 Cr.
The company currently has active open charges totaling ₹79.92 Cr.
Samir Shah, Mahesh Shah, Rohan Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304MH2017PTC292537
- Company No.
292537
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Skites Pharma Private Limited offer?
Skites Pharma Private Limited offers a wide range of products and services, including Disposable & Other Optical Lenses, Contact Lens Accessories.
Who are the key members and board of directors at Skites Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohan Shah  | Director | 16-Mar-2017 | Current |
| Samir Shah | Director | 16-Mar-2017 | Current |
| Mahesh Shah | Director | 13-Feb-2018 | Current |
Eishi Maekawa  | Director | 16-Jul-2021 | Current |
Financial Performance and Corporate Structure Insights of Skites Pharma.
Skites Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 39.55% increase. The company also saw a slight improvement in profitability, with a 0.5% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skites Pharma?
In 2023, Skites Pharma had a promoter holding of 100.00%. The company had 4 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 22 Jun 2018 | ₹79.92 Cr | Open |
How Many Employees Work at Skites Pharma?
Skites Pharma has a workforce of 459 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skites Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skites Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
